Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 60 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE from Steenokkerzeel, company number BE0784236189, closed financial year 2025 with a result of € 108,717 after tax. For that financial year DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE recorded a gross margin of € 141,000 and equity of € 5,000. Compared with financial year 2024, the result moved from € 84,119 to € 108,717. Profitable, and profit is growing. The buffer shrank hard: equity is 98 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 5,000
▼ 98% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 108,717
▲ 29% vs 2024
Profit after tax over the fiscal year.
€ 70,821
▼ 33% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 347,869 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 9,700
▲ 40% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 101,998 | € 95,062 | € 107,803 | € 141,000 | ▲ 31% |
| Profit after taxes | € 80,424 | € 74,610 | € 84,119 | € 108,717 | ▲ 29% |
| Equity | € 85,424 | € 160,034 | € 244,153 | € 5,000 | ▼ 98% |
| Total debts | € 12,986 | € 11,729 | € 9,781 | € 118,878 | ▲ € 109,098 |
| Cash | € 54,872 | € 127,838 | € 105,304 | € 70,821 | ▼ 33% |
| Retained profit | € 80,424 | € 155,034 | € 239,153 | € 0 | ▼ 100% |
| Dividend | € 0 | € 0 | € 0 | € 347,869 | |
| Balance sheet total | € 98,410 | € 171,763 | € 253,933 | € 123,878 | ▼ 51% |
Key figures of DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE?
What happened at DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 108,717 (▲ 29% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Steenokkerzeel. KBO
- Els Delaunay became a director. NBB
In short
From € 80,424 profit in 2022 to € 108,717 profit in 2025.
Paid € 96,105 in corporate taxes since 2022.
Best year ever: 2025, with € 108,717 profit.
Paid out € 347,869 in dividends to the owners in total.
Management
Behind DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE is Els Delaunay.
Directors
According to the 2025 annual accounts
Els Delaunay
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Sinte Veerledreef 5 box 1
1820 Steenokkerzeel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- DELAUNAY Els Rosa Joanna Maria(oprichter) 100%
Details
- Company number
- 0784.236.189
- VAT number
- BE 0784.236.189
- Registered office
- Sinte Veerledreef 5 bus 1, 1820 Steenokkerzeel
- Names & denominations
- DELAUNAY ELS, ENDOCRINO-DIABETOLOGIE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 March 2022
- Peppol
- Active · Active since 6 Jan 2026